Multi-kinase-IN-4 

Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC₅₀ values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC₅₀ = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC₅₀ = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer^[1].

Multi-kinase-IN-4 (compound 5d) (48 h) has cytotoxic against the HepG2, MCF-7, MDA-231, and HeLa cell lines with IC₅₀ values of 7.10, 2.48, 1.94, and 6.38 µM, respectively, but displays less cytotoxic activity on the WI38 cells (IC₅₀ = 64.29 µM) ^[1].
Multi-kinase-IN-4 (7.1 µM, 24 h, HepG2 cells ) increases the cell population of 9.23% at the S phase and results in a drop in the cell population at the G0-G1 and G2/M phases: 4.50% and 4.73%, respectively^[1].
Multi-kinase-IN-4 (7.1 µM, 24 h, HepG2 cells) induces early and late apoptosis as well as necrotic cell death by 7.51%, 3.45%, and 3.08%, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

402.91

C₂₁H₂₀ClFN₂OS

O=C1N(C/C=C(CC)\C)C(SCC2=CC=C(Cl)C=C2)=NC3=C1C=C(F)C=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ali Altharawi, et al. Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study. Molecules. 2023 Jul; 28(14): 5548.